Figure 5 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
Year: 2023
Type: other
Abstract: Increased 177Lu-DOTATATE uptake induced by CI-994 treatment promotes tumor regression in QGP-1 xenograft model. A, Tumor volume (mm3) ± SEM from start to the end of pretreatment with CI-994 and injection of 30 MBq 177Lu-DOTATATE at day 0 (arrow). Mice were then observed for tumor growth responses to 177Lu-DOTATATE for 15 days. Day 11: control vs. CI-994 + 177Lu-DOTATATE (P = <0.0001); control + 177Lu-DOTATATE vs. CI-994 + 177Lu-DOTATATE (P = 0.0008). Day 15: control versus CI-994 + 177Lu-DOTATATE (P <0.0001); control + 177Lu-DOTATATE versus CI-994 + 177Lu-DOTATATE (P = 0.0028). B, Weight (g) ± SEM of mice from start to the end of treatment with CI-994 and 177Lu-DOTATATE. Control n = 18, Control +177Lu-DOTATATE n = 18, CI-994 n = 4, CI-994 + 177Lu-DOTATATE n = 10. Data are expressed as mean ± SEM. C, Representative images of QGP-1 xenograft tumors collected after euthanasia, comparing the combination CI-994 +177Lu-DOTATATE therapy group to the control + 177Lu-DOTATATE group.
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4386475093